We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Radiosurgical Neuromodulation for Refractory Depression

This study has been terminated.
(Potential AE)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01403441
First Posted: July 27, 2011
Last Update Posted: September 4, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hugh Brent Solvason, Stanford University
  Purpose
This study is designed to evaluate the safety and effectiveness of an investigational procedure for treating people with treatment resistant bipolar depression (TRD). Precise dose delivery of radiation to the predetermined targets in the brain will be accomplished with known Cyberknife stereotactic radiosurgery methods. This technology is considered to be noninvasive (does not physically invade your body). We will be studying if the Cyberknife influences the sensitivity of certain nerves of your brain. Although many clinical treatments for psychiatric conditions have been done using stereotactic radiosurgery, the present study is experimental, because we are seeking to use more moderate doses of radiation that are intended not to destroy any brain cells, but to normalize or modulate their function.

Condition Intervention
Bipolar Disorder Device: Radiosurgical Neuromodulation using the Cyberknife

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Intervention Model Description:
Precision radiotherapy is delivered on Day 1 using the Cyberknife System to Brodmann area cingulate 25.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Radiosurgical Neuromodulation for Refractory Depression

Resource links provided by NLM:


Further study details as provided by Hugh Brent Solvason, Stanford University:

Primary Outcome Measures:
  • Serious Adverse Event [ Time Frame: Baseline and 12 months. ]
    An event that required hospitalization due to an unanticipated worsening of the subjects bipolar disorder.


Secondary Outcome Measures:
  • Hamilton Depression Rating Scale (HDRS) - 17 Item [ Time Frame: Baseline and 12 months ]
    The HDRS is a rating scale measures the severity of depressive symptoms. The scale consists of 17 symptoms with severity anchors that are scored from 0 to 4. The maximum score (most severe depression) is 68, the lowest (no depressive symptoms) is 0.

  • Clinical Global Impression - Severity (CGI-S) at Baseline and 12 Months [ Time Frame: Baseline and 12 months ]
    The CGI-S assess the overall severity of depression over the 12 month observation period following Cyberknife System. It is rated from 1 (well or remitted) to 7 (severely ill, among the most depressed).

  • Delis-Kaplan Executive Function System (D-KEFS) Composite Score [ Time Frame: Baseline and 12 months ]
    D-KEFS is a neurocognitive assessment of executive function. The composite score is derived from scores on tests that include Trails A, Color Word Interference, Verbal Fluency, Sorting, WAIS III Digit Span, and CVLT II Long Delay Free Recall. The scores are reported as deviation from a mean of 10, with a standard deviation of 3. A score of 7 is one standard deviation below the mean, while a score of 13 is 1 standard deviation above the mean. Higher numeric outcomes reflect better performance on the test, lower values reflect poorer performance. Results reflect scores at baseline, and 12 month observation period following Cyberknife System


Enrollment: 3
Study Start Date: July 2010
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Radiosurgical Neuromodulation
Bilateral Radiosurgical Neuromodulation using the Cyberknife
Device: Radiosurgical Neuromodulation using the Cyberknife
our team has selected 60 Gray (Gy) as the dose to the target margin to be used for radiosurgical neuromodulation in patients with intractable bipolar disorder; the target being the anterior cingulate (Cg) that correlates with Brodmann area 25 (Cg25).

Detailed Description:

Main objective: To determine the safety of Radiosurgical Neuromodulation (RSN) for Refractory Depression using X-rays in a population of subjects with severe treatment resistant bipolar depression over a 12-month observational period post treatment. While almost any radiosurgical device could be used, the research team has extensive experience with the Accuray CyberKnife System, K011024, and it will be used for planning and delivery of the 6 megavolt (MV) X-ray treatment for this study.

Participation will be dependent upon subjects having a diagnosis of bipolar depression and meeting criteria for treatment resistance. Treatment resistance will be defined as a failure to show clinical improvement after at least four different medication trials and/or one course of electroconvulsive therapy (ECT) during the current episode. A medication trial is defined as an adequate dose and duration of one of four classes of psychoactive medications: lithium, anticonvulsant mood stabilizers, atypical antipsychotic mood stabilizers, and/or antidepressant medications. One course of ECT is defined as receiving six acute treatments. The study will include subjects who have failed ECT, or have had intolerable side effects to ECT, or elected not to receive such treatment due to stigma, or concern over possible side effects of the ECT treatment itself. The subjects enrolled will have exhausted all reasonable treatment strategies, and currently have no other reasonable or viable treatment options for their illness.

Secondary objective: To examine clinical outcome initially over 3 months, then with follow up at 6, 9 and 12 months. Depression will be assessed using the Hamilton Depression Rating Scale (HDRS) 24 item, while manic symptoms will be measured by using the Young Mania Rating Scale (YMRS), and the Clinical Global Impression of Severity of illness (CGI-S), and Improvement (CGI-I). A battery of neuropsychological tests will be administered as well, assessing memory with the California Verbal Learning Task (CVLT), prefrontal function using a Delas-Kaplan Executive Function System (DKEFS) battery including the DKEFS Sorting task, DKEFS Trails task, DKEFS color-word interference task, and the DKEFS verbal fluency task. In addition, the investigators will request information regarding any possible adverse events that occur during this trial.

The intended use for the CyberKnife System, the radiosurgical device being used in this research study, is to administer radiomodulation to the cingulate cortex target Cg25 in patients with refractory bipolar depression.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   22 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

In order to be eligible to participate, all patients must meet the following criteria:

  • Men and women 22-65 years of age
  • Primary diagnosis of bipolar depression, as per the Diagnostic and Statistical Manual - Text Revision (DSM IV-TR) criteria
  • The current major depressive episode has been for at least one year
  • Hamilton Depression Rating Scale (HDRS)-24 item greater than or equal to 20
  • Negative urine pregnancy in female subjects
  • No current psychotic symptoms
  • No comorbid post traumatic stress disorder, the inclusion of subjects with other psychiatric comorbidity will be determined by the investigator prior to enrollment
  • No personality disorder that in the opinion of the investigator may compromise the subjects ability to participate and be compliant with the elements and procedures of the study
  • No substance abuse of dependence in the last 6 months
  • A negative urine drug screen
  • On a stable dose of their current medication regimen for four weeks
  • Treatment resistance: A history of failure to show clinical improvement after at least four different medication trials of adequate duration and dose and one course of ECT. A course of ECT is not mandatory for those who have declined the procedure due to stigma, patient preference, or intolerance. One course of ECT is defined as receiving six acute treatments. (Note: the Antidepressant Treatment History Form (ATHF) does not apply to bipolar depression where mood stabilizers are the treatments of choice in the first three steps in an algorithm to treat bipolar depression)
  • No available reasonable treatment options at the time of enrollment
  • Competent to understand the risks and potential benefits of the study
  • Able to provide written informed consent for the full screening phase, as well as the treatment period of the protocol, including the baseline MRI, CT and positron emission tomography (PET) imaging
  • Signed consent form for participation in the study

Exclusion Criteria:

Patients who meet the following criteria will be excluded from participation in this research study:

  • Rapid cycling bipolar illness
  • History of schizophrenia, schizoaffective disorder, or psychosis
  • Severe suicidal thoughts that may put the subject at risk of either an attempted suicide or completed suicide for the duration of the trial, as determined by the investigator at the time of enrollment
  • Current substance abuse or in the process of withdrawal from mind-altering substances including alcohol, stimulants, or sedatives
  • Undisclosed or undiagnosed unstable medical or neurologic illness including stroke, significant brain malformation, brain mass
  • Previous whole-brain radiation
  • Brain-implanted devices such as deep brain stimulation leads, aneurysm clips
  • A history of seizure disorder
  • History of moderate to severe brain injury
  • Current treatment with either metronidazole or cisplatinum and an inability to discontinue prior to RSN
  • Pregnancy or breast feeding
  • Unstable medical illness
  • Current participation in another investigational trial or participation within 30 days of enrollment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01403441


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Hugh Brent Solvason Stanford University
  More Information

Responsible Party: Hugh Brent Solvason, Associate Professor, Stanford University
ClinicalTrials.gov Identifier: NCT01403441     History of Changes
Other Study ID Numbers: SU-12012010-7249
eprotocol 10186
First Submitted: July 25, 2011
First Posted: July 27, 2011
Results First Submitted: October 10, 2016
Results First Posted: September 4, 2017
Last Update Posted: September 4, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Hugh Brent Solvason, Stanford University:
Refractory Bipolar Depression

Additional relevant MeSH terms:
Depression
Bipolar Disorder
Depressive Disorder, Treatment-Resistant
Behavioral Symptoms
Bipolar and Related Disorders
Mental Disorders
Depressive Disorder
Mood Disorders